A 52-year-old woman with chronic kidney disease (eGFR 28 mL/min/1.73m²) presents with serum calcium 7.2 mg/dL, phosphate 5.8 mg/dL, and PTH 280 pg/mL. Regarding the pathophysiology of secondary hyperparathyroidism in CKD, all of the following are true EXCEPT:

Explanation

## Secondary Hyperparathyroidism in CKD: Pathophysiology **Key Point:** Option 2 is incorrect. PTH-mediated bone resorption in CKD is NOT protective—it is pathologic and leads to renal osteodystrophy, not prevents it. ### The Vicious Cycle of Secondary Hyperparathyroidism: ```mermaid flowchart TD A[CKD: ↓ GFR]:::outcome --> B[↓ Renal 1α-hydroxylase]:::outcome B --> C[↓ Calcitriol production]:::outcome C --> D[↓ Intestinal Ca²⁺ absorption]:::outcome D --> E[↓ Serum Ca²⁺]:::outcome E --> F[↑ PTH secretion]:::action A --> G[↑ Serum phosphate]:::outcome G --> H[Direct PTH stimulation]:::action G --> I[↑ FGF23]:::outcome I --> J[Further ↓ Calcitriol]:::outcome F --> K[Parathyroid hyperplasia]:::action K --> L[Excessive bone resorption]:::urgent L --> M[Renal osteodystrophy]:::urgent ``` ### Correct Statements (Options 0, 1, 3): **Option 0 — Calcitriol Deficiency:** - CKD reduces renal 1α-hydroxylase expression - ↓ Calcitriol → ↓ intestinal Ca²⁺ absorption - Contributes to hypocalcemia and secondary hyperparathyroidism - **TRUE** **Option 1 — Hyperphosphatemia as Direct Stimulus:** - Elevated serum phosphate directly suppresses FGF23-independent PTH secretion - Hyperphosphatemia also promotes parathyroid cell proliferation - This occurs even when calcitriol levels are low - **TRUE** [cite:Kidney Disease: Improving Global Outcomes (KDIGO) 2017] **Option 3 — FGF23 Elevation:** - FGF23 rises early in CKD (even with normal GFR) in response to hyperphosphatemia - FGF23 suppresses 1α-hydroxylase → ↓ calcitriol - FGF23 also promotes renal phosphate excretion (but cannot overcome declining GFR) - **TRUE** ### Why Option 2 is Wrong (Bone Resorption is NOT Protective): **Clinical Pearl:** Excessive PTH-driven bone resorption in CKD causes **renal osteodystrophy**, a spectrum of bone disorders: | Type | Mechanism | Consequence | |------|-----------|-------------| | **High-turnover bone disease** | ↑ PTH → ↑ osteoclast activity | Bone loss, fractures, pain | | **Low-turnover bone disease** | Oversuppression of PTH (from calcitriol/cinacalcet) | Adynamic bone, impaired healing | | **Mixed uremic osteodystrophy** | Combination of above + aluminum toxicity | Severe skeletal morbidity | **High-Yield:** PTH-mediated bone resorption in CKD is **maladaptive**, not protective. It leads to: - Bone loss and increased fracture risk - Vascular and soft-tissue calcification (from released calcium and phosphate) - Accelerated cardiovascular disease **Warning:** Do not confuse the physiologic role of PTH in normal calcium homeostasis (which is protective) with its pathologic role in CKD (which causes osteodystrophy). ### Management Implications: Secondary hyperparathyroidism is managed by: 1. **Phosphate binders** (calcium-free preferred to avoid hypercalcemia) 2. **Calcitriol or calcitriol analogs** (to suppress PTH) 3. **Calcimimetics** (cinacalcet: allosteric CaSR activator) 4. **Parathyroidectomy** (if medical therapy fails) [cite:KDIGO 2017 CKD-MBD Guidelines; Harrison 21e Ch 298]